Convolutional neural network in proteomics and metabolomics for determination of comorbidity between cancer and schizophrenia
Arthur T. Kopylov, Denis V. Petrovsky, Alexander A. Stepanov, Vladimir R. Rudnev, Kristina A. Malsagova, Tatiana V. Butkova, Natalya V. Zakharova, Georgy P. Kostyuk, Liudmila I. Kulikova, Dmitry Enikeev, Natalia V. Potoldykova, Д. А. Куликов, Aleksei Zulkarnaev, Anna L. Kaysheva
Abstract
The association between cancer risk and schizophrenia is widely debated. Despite many epidemiological studies, there is still no strong evidence regarding the molecular basis for the comorbidity between these two pathological conditions. The vast majority of assays have been performed using clinical records of schizophrenic patients or those undergoing cancer treatment and monitored for sufficient time to find shared features between the considered conditions. We performed mass spectrometry-based proteomic and metabolomic investigations of patients with different cancer phenotypes (breast, ovarian, renal, and prostate) and patients with schizophrenia. The resulting vast quantity of proteomic and metabolomic data were then processed using systems biology and one-dimensional (1D) convolutional neural network (1DCNN) machine learning approaches. Traditional systematic approaches permit the segregation of schizophrenia and cancer phenotypes on the level of biological processes, while 1DCNN recognized "signatures" that could segregate distinct cancer phenotypes and schizophrenia at the comorbidity level. The designed network efficiently discriminated unrelated pathologies with a model accuracy of 0.90 and different subtypes of oncophenotypes with an accuracy of 0.94. The proposed strategy integrates systematic analysis of identified compounds and application of 1DCNN model for unidentified ones to reveal the similarity between distinct phenotypes.